ChemInform Abstract: Structure and Metabolic Fate of N-Nitrosodialkylamines in Relation to Their Organotropic Carcinogenicity with Special Reference to Induction of Urinary Bladder Tumors

ChemInform ◽  
2010 ◽  
Vol 29 (17) ◽  
pp. no-no
Author(s):  
M. MOCHIZUKI ◽  
E. SUZUKI ◽  
M. OKADA
Keyword(s):  
Urinary Bladder ◽  
Special Reference ◽  
Metabolic Fate ◽  
Bladder Tumors ◽  
Abstract Structure

scholarly journals Sarcomatoid Carcinoma of the Urinary Bladder Treated with Adjuvant Radiotherapy: A Case Report

2009 ◽  
Vol 2 ◽  
pp. CCRep.S3126 ◽  
Author(s):  
Cem Onal ◽  
Berrin Pehlivan ◽  
Nebil Bal ◽  
Erkan Topkan ◽  
Ferhat Kilinc ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Local Treatment ◽  
Sarcomatoid Carcinoma ◽  
Conformal Radiotherapy ◽  
Total Abdominal Hysterectomy ◽  
Abdominal Hysterectomy ◽  
Wall Thickening ◽  
Bladder Tumors ◽  
Large Tumor ◽  
3D Conformal Radiotherapy

Sarcomatoid carcinoma is a rare tumor of the urinary bladder accounting for less than 0.5% of all primary urinary bladder tumors. Since the patients were presented with large tumor with extended stages, outcome was found to be poor. In order to improve local control, adjuvant local treatment may be practical. We report a rare case with sarcomatoid carcinoma of the urinary bladder diagnosed with immunuhistochemical (IHC) study and treated with 3D-conformal radiotherapy (3DCRT) post-operatively. A 55-year old female patient complained about painless hematuria for 2 months. Computed tomography of the pelvic region revealed tumor and wall thickening at the left posterolateral side of the bladder. Total cystectomy with lymph node dissection and total abdominal hysterectomy and bilateral salphingo-oopherectomy was performed and histopathological and immunohistochemical findings strongly correlate with sarcomatoid carcinoma. The patient was treated with 3D conformal radiotherapy (3DCRT) with a total dose of 59.4 Gy with 1.8 Gy fractional daily doses. Patient was alive without any local recurrence and distant metastasis 10 months after surgery.

C118 Nuclear matrix protein 22 urinary marker in diagnosing and follow up of urinary bladder tumors

2009 ◽  
Vol 8 (8) ◽  
pp. 696
Author(s):  
T. Smrkolj ◽  
M. Mihelic ◽  
A. Sedlar ◽  
I. Sterle ◽  
J. Osredkar ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Nuclear Matrix ◽  
Matrix Protein ◽  
Bladder Tumors ◽  
Nuclear Matrix Protein ◽  
Urinary Marker

scholarly journals Functional Bladder Paraganglioma Treated by Partial Cystectomy

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
Amine Hermi ◽  
Hamza Ichaoui ◽  
Aziz Kacem ◽  
Houcem Hedhli ◽  
Faten Gargouri ◽  
...  
Keyword(s):  
Nervous System ◽  
Autonomic Nervous System ◽  
Urinary Bladder ◽  
Neuroendocrine Tumor ◽  
Transurethral Resection ◽  
Partial Cystectomy ◽  
Treatment Modalities ◽  
Rare Tumor ◽  
Bladder Tumors ◽  
Specific Symptoms

Paraganglioma is a rare neuroendocrine tumor that arises from the autonomic nervous system. The urinary bladder paraganglioma accounts for less than 0.1% of bladder tumors. It remains a challenging entity to diagnose and treat due to its rareness and the lack of specific symptoms. Treatment modalities include transurethral resection and cystectomy (partial or total). The authors report a new case of an isolated paraganglioma of the urinary bladder in a 52-year-old female patient that underwent partial cystectomy. This case aims to remind the clinical, histological and therapeutic features of this rare tumor.

Unique clinicopathologic and molecular characteristics of urinary bladder tumors in children and young adults

2013 ◽  
Vol 31 (4) ◽  
pp. 414-426 ◽  
Author(s):  
Sean R. Williamson ◽  
Antonio Lopez-Beltran ◽  
Gregory T. MacLennan ◽  
Rodolfo Montironi ◽  
Liang Cheng
Keyword(s):  
Young Adults ◽  
Urinary Bladder ◽  
Molecular Characteristics ◽  
Bladder Tumors ◽  
Children And Young Adults

Immunohistochemical Detection of Uroplakin III, Cytokeratin 7, and Cytokeratin 20 in Canine Urothelial Tumors

2003 ◽  
Vol 40 (1) ◽  
pp. 55-62 ◽  
Author(s):  
J. A. Ramos-Vara ◽  
M. A. Miller ◽  
M. Boucher ◽  
A. Roudabush ◽  
G. C. Johnson
Keyword(s):  
Urinary Bladder ◽  
Transitional Cell ◽  
Cytokeratin 20 ◽  
Cytokeratin 7 ◽  
Bladder Tumors ◽  
Cytoplasmic Staining ◽  
Negative Results ◽  
Urothelial Tumors ◽  
Carcinoma Of The Bladder ◽  
Intermediate Cells

Immunohistochemistry for uroplakin III (UP III), cytokeratin 7 (CK 7), and cytokeratin 20 (CK 20) using commercially available antibodies was done in normal canine urinary bladder and 72 canine urinary bladder tumors that had been fixed in formalin and embedded in paraffin. Prolonged fixation (3–28 days) did not significantly alter the immunostaining for UP III. There was moderate reduction in the intensity for CK 7 and CK 20 after 1 week of fixation. UP III was detected in superficial (umbrella) cells and some intermediate cells of the normal urinary bladder, 7 of 7 transitional cell papillomas (TCPs), 50 of 55 transitional cell carcinomas (TCCs), and 4 of 5 metastatic TCCs. Staining was typically outlined in the plasma membrane, but diffuse or focal cytoplasmic staining was also observed. Intracytoplasmic lumina were usually positive for UP III. One squamous cell carcinoma of the bladder, 4 nonepithelial bladder tumors, and 285 nonurothelial tumors from different nonurinary locations were negative for UP III. CK 7 was detected in 7 of 7 TCPs, 53 of 54 TCCs, and 5 of 5 metastatic TCCs. The staining for CK 7 was diffuse cytoplasmic. CK 20 was detected in 1 of 7 TCPs, 37 of 54 TCCs, and 1 of 5 metastatic TCCs. The staining with CK 20 was cytoplasmic and weaker than with antibodies to UP III or CK 7. There was concurrent expression of UP III, CK 7, and CK 20 in 36 of 54 TCCs. UP III is a specific and sensitive marker for canine transitional epithelial (urothelial) neoplasms, detecting 91% of TCCs. Negative results may be observed with anaplastic tumors.

Sign in / Sign up

Export Citation Format

Share Document